Patients with advanced lung cancer harboring oncogenic mutations should be admitted to intensive care units

Intensive Care Med. 2015 Jan;41(1):164-5. doi: 10.1007/s00134-014-3535-x. Epub 2014 Nov 4.
No abstract available

Publication types

  • Letter
  • Multicenter Study

MeSH terms

  • Biomarkers, Tumor / genetics
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Carcinoma, Non-Small-Cell Lung / pathology*
  • Carcinoma, Non-Small-Cell Lung / therapy
  • ErbB Receptors / genetics
  • Female
  • France / epidemiology
  • Humans
  • Intensive Care Units / statistics & numerical data*
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / mortality
  • Lung Neoplasms / pathology*
  • Lung Neoplasms / therapy
  • Male
  • Middle Aged
  • Mutation*
  • Oncogene Proteins, Fusion / genetics
  • Patient Admission*
  • Protein-Tyrosine Kinases / genetics
  • Proto-Oncogene Proteins / genetics
  • Survival Analysis
  • Treatment Outcome

Substances

  • Biomarkers, Tumor
  • EML4-ALK fusion protein, human
  • Oncogene Proteins, Fusion
  • Proto-Oncogene Proteins
  • EGFR protein, human
  • ErbB Receptors
  • Protein-Tyrosine Kinases
  • ROS1 protein, human